Addendum

Fremanezumab (migraine) - Addendum to Commission A19-44

Report documents

Indication:

Migraine prophylaxis in adult patients with at least 4 migraine days per month

Result of dossier assessment:

Based on subsequently submitted analyses, there is now an indication of non-quantifiable added benefit

2019-11-07 A G-BA decision was published.

Project no.: A19-82
Commission: Commission awarded on 24.09.2019 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Head and nerves
Note: If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.